Table 1.
Lymph node involvement and clinicopathological characteristics of all pT1 patients, n (%)
| Characteristics | pN0 (n = 263) | pN1 (n = 28) | pN1+N2 (n = 19) | pN2 (n=15) | P value |
|---|---|---|---|---|---|
| Age (mean), yrs. | 62 ± 9 | 61 ± 7 | 59 ± 9 | 58 ± 7 | |
| ≤60 | 101 (31.1) | 12 (3.7) | 7 (2.2) | 10 (3.1) | 0.185 |
| >60 | 162 (49.8) | 16 (4.9) | 12 (3.7) | 5 (1.5) | |
| Gender | |||||
| Male | 145 (44.6) | 22 (6.8)a | 14 (4.3) | 6 (1.8) | 0.020 |
| Female | 118 (36.3) | 6 (1.8) | 5 (1.5) | 9 (2.8) | |
| Tobacco smoking history | |||||
| Never | 147 (45.2) | 18 (5.5) | 6 (1.8)b | 9 (2.8) | 0.044 |
| Ever/current | 116 (35.7) | 10 (3.1) | 13 (4.0) | 6 (1.8) | |
| CEA level (n = 395) | |||||
| <5.0 IU/mL | 216 (66.5)c | 16 (4.9) c | 9 (2.8) | 9 (2.8) | <0.0001 |
| ≥5.0 IU/mL | 47 (14.5) | 12 (3.7) | 10 (3.1) | 6 (1.8) | |
| Tumor location | |||||
| Upper lobe | 154 (47.4) | 12 (3.7) | 10 (3.1) | 10 (3.1) | 0.150 |
| Middle lobe | 18 (5.5) | 2 (0.6) | 1 (0.3) | 2 (0.6) | |
| Lower lobe | 87 (26.8) | 12 (3.7) | 6 (1.8) | 2 (0.6) | |
| Middle-lower lobe | 4 (1.2) | 2 (0.6) | 2 (0.6) | 1 (0.3) | |
| Type of surgery | |||||
| Lobectomy | 235 (72.3) | 23 (7.1) | 17 (5.2) | 13 (4.0) | 0.720 |
| Limited resection | 28 (8.6) | 5 (1.5) | 2 (0.6) | 2 (0.6) | |
| Adjuvant chemotherapy | |||||
| No | 166 (51.1)d | 0d | 0d | 0d | <0.0001 |
| Yes | 97 (29.8) | 28 (8.6) | 19 (5.8) | 15 (4.6) | |
| Tumor size, cm | |||||
| ≤1.0 | 28 (8.6)e | 0e | 0 | 0 | 0.021 |
| 1.0–≤2.0 | 153 (47.1) | 12 (3.7) | 10 (3.1) | 7 (2.2) | |
| 2.0–≤3.0 | 82 (25.2) | 16 (4.9) | 9 (2.8) | 8 (2.5) | |
| Histology | |||||
| IAC | 220 (67.7)f | 12 (3.7)f | 10 (3.1)f | 11 (3.4)f | <0.0001 |
| SCC | 43 (13.2) | 16 (4.9) | 9 (2.8) | 4 (1.2) | |
CEA carcinoembryonic antigen, IAC invasive lung adenocarcinoma, SCC squamous cell lung cancer
aMale vs. female
bnever smoked tobacco vs. ever/current
cCEA level <5.0 IU/mL vs. ≥5.0 IU/mL
dno adjuvant chemotherapy vs. adjuvant chemotherapy
etumor size ≤1.0 vs. 1.0–≤2.0 vs. 2.0–≤3.0
fIAC vs. SCC